Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Haemonetics Corp.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.
Boston Scientific will exercise its option to buy the remaining 73% of Farapulse, the first company to market a pulsed field cardiac ablation system.
The company is supporting two US trials of the AcQBlate Force ablation catheter to support FDA approval of the system to treat atrial flutter and atrial fibrillation.